Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.

EJHaem · 2023 · PMC10188506 · PMID 37206258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, ex vivo PharmaFlow analyses in samples of patients treated with the combination showed a trend of correlations between the sensitive ex vivo classification and clinical responses, but a larger sample is needed to confirm these results.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.